BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRXBiotechnology
+$0.09 today
- Market cap
- $1.88B
- Beta
- 0.56
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.89
Volume 2.95M
Average 4.85M
BCRX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $78.4M rose 1441.7% year over year, ahead of the +651.2% change in trailing-twelve-month net income.
Context
- Net income amounted to 30.2% of revenue in FY2025, up 10.4 pp from a year earlier.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$501.77M (-290.2%) for the fiscal year ending Dec 2026, a slowdown from the +396.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $78.4M+110.9% QoQ
- Last fiscal yearDec 2025
- $263.86M+396.9% YoY
- LTMJun 2026
- -$268.25M+651.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1441.7% | +90.6% | -1351.1 pp |
| 1 year | +396.9% | -290.2% | -687.0 pp |
| 3-year CAGR | — | -24.2% | — |
| 5-year CAGR | -1.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 263.86M USD
- Year-over-year change
- +396.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 263.86M | +396.9% |
| FY2024 | 2024-12-31 | (88.88M) | +60.8% |
| FY2023 | 2023-12-31 | (226.54M) | +8.3% |
| FY2022 | 2022-12-31 | (247.12M) | -34.3% |
| FY2021 | 2021-12-31 | (184.06M) | — |
Net Income vs competitors
How BCRX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +651.2% is the highest of 4, against a peer median of +11.0%.
- Net income amounts to 28.5% of revenue for BCRX, versus a peer median of 676.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $442.72M USD | -23.4% | — | 676.0% | |
| LTM Jun 2026 | $268.25M USD | +651.2% | — | 28.5% | |
| LTM Sep 2026 | €179.96M EUR | +11.0% | +31.9% | — | |
| LTM Mar 2026 | $169.52M USD | +21.5% | +11.0% | — | |
| Peer median (excluding BCRX) | — | +11.0% | +21.4% | 676.0% | |
Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (184.06M) | (247.12M) | (226.54M) | (88.88M) | 263.86M |
| Depreciation & Amortization | 777K | 1.44M | 1.66M | 1.25M | 1.39M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 34.64M | 44.7M | 55.62M | 65.41M | 85.07M |
| Change in Working Capital | 8.12M | (58.95M) | (32.4M) | (87.28M) | (56.9M) |
| Accounts Receivables | (20.82M) | (21.47M) | (6.1M) | (22.7M) | (36.81M) |
| Inventory | (8.77M) | (12.42M) | (1.45M) | (4.16M) | (1.64M) |
| Accounts Payables | 39.41M | (22.36M) | (16.81M) | (62.38M) | 57.8M |
| Other Working Capital | (1.7M) | (2.69M) | (8.05M) | 1.96M | (76.26M) |
| Other Non-Cash Items | (1.64M) | 98.07M | 106.53M | 57.48M | 36.46M |
| Operating Cash Flow | (142.16M) | (161.85M) | (95.14M) | (52.02M) | 329.88M |
| Capital Expenditures | (2.39M) | (1.35M) | (2.17M) | (1.12M) | (2.47M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (6.18M) |
| Purchases of Investments | (10.01M) | (244.28M) | (514.41M) | (266.76M) | (262.24M) |
| Sales of Investments | 28.2M | 117.4M | 385.08M | 320.48M | 256.65M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 550K |
| Investing Cash Flow | 15.8M | (128.24M) | (131.5M) | 52.59M | (13.69M) |
| Debt Repayment | 293.87M | 73.07M | 58.38M | (1.7M) | (332.77M) |
| Common Stock Issued | 50.06M | 190K | 342K | 34K | 9.17M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 15.73M | 14.77M | (26.24M) | (4.09M) | (8.85M) |
| Financing Cash Flow | 359.67M | 88.03M | 32.49M | (5.76M) | (332.44M) |
| Effect of Forex Changes | 71K | 566K | 362K | (936K) | (87.07M) |
| Net Change in Cash | 233.39M | (201.5M) | (193.79M) | (6.12M) | (103.32M) |
| Free Cash Flow | (144.54M) | (163.2M) | (97.31M) | (53.14M) | 327.41M |
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
Intrinsic Alpha fair value
Locked
Current Price
$7.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.